{
    "2019-01-07": [
        [
            {
                "time": "",
                "original_text": "智飞生物净利润预增两倍 现金流却很不给力",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "净利润",
                        "预增",
                        "现金流"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2019年度A+H策略报告:大破大立,不经一番寒彻骨,怎得梅花扑鼻香",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2019年度",
                        "A+H策略",
                        "大破大立"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}